Mepolizumab
From Wikipedia, the free encyclopedia
|
Mepolizumab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Human |
| Target | IL-5 |
| Identifiers | |
| CAS number | ? |
| ATC code | L04 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 19 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mepolizumab (marketing name Bosatria) is a humanized monoclonal antibody that recognizes the IL-5 protein. It is currently in development for the management of hypereosinophilic syndrome by GlaxoSmithKline (GSK) and has received orphan drug designation by the FDA.[1]
Previously, the drug was investigated in larger indications where eosinophils play an important role in the disease progression. Phase II trials in asthma were underway by April 1998 and by March 2002, phase II trials had also been initiated in atopic dermatitis. Mepolizumab had little efficacy in preclinical or clinical studies for [atopic dermatitis] [2] and it failed to sufficiently deplete eosinophils in clinical trials for asthma [3]. GSK's recent strategy has focused on gaining orphan-drug status and pursuing hypereosinophilic syndrome.
[edit] References
- ^ Phase III study of Bosatria (mepolizumab) showed disease control with reduced corticosteroid use in hypereosinophilic syndrome
- ^ No Effect of Anti-Interleukin-5 Therapy (Mepolizumab) on the Atopy Patch Test in Atopic Dermatitis Patients
- ^ Eosinophil's role remains uncertain as anti-interl...[Am J Respir Crit Care Med. 2003] - PubMed Result
|
|||||||||||||||||||||||
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
